Ancient herbs take on stubborn heart pain in seniors
NCT ID NCT07041359
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two traditional Chinese medicines—Compound Danshen Dripping Pills and Qishen Yiqi Dripping Pills—can reduce chest pain and improve quality of life in elderly patients (75-90 years old) with coronary heart disease who still have symptoms despite standard treatment. 120 participants will receive either one of the herbal pills or a placebo, alongside their usual medications. The goal is to see if these herbs safely ease symptoms like angina and shortness of breath.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Compound Danshen Dripping Pills and Qishen Yiqi Dripping Pills
- What this could lead to
- If successful, this could provide a safe add-on option to reduce angina symptoms and improve daily life for elderly heart disease patients who still have symptoms despite standard treatment.
- What could go wrong
- This is a small, early-phase trial (120 participants) focused on symptom relief, not a cure. The benefits may be modest, and results may not apply to all patients. Risks include potential herb-drug interactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
75 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 75 years old ≤ age \< 90 years old, regardless of gender; 2. Patients who meet the diagnostic criteria for angina pectoris, including patients with typical or atypical angina pectoris: discomfort in the anterior region is triggered by physical activity or emotional excitement and can be relieved by rest or taking nitroglycerin.Those who meet two or more of the above characteristics. After receiving conventional Western medicine treatment, the symptoms did not improve significantly or the treatment effect is poor. 3. Meet the diagnostic criteria for multiple coronary artery disease with the number of coronary artery disease being greater than or equal to two (defined as angiographically the right coronary artery, left circumflex artery or left anterior descending artery stenosis rate was greater than 50%), and the patient refused or could not tolerate coronary artery revascularization or one or more coronary arteries still have a stenosis rate of ≥50% after partial revascularization; 4. The patient is in line with the qi stagnation and blood stasis type or qi deficiency and blood stasis type in the TCM syndrome classification. If the results of the two syndrome differentiation are inconsistent, the TCM experts will review the syndrome differentiation, and the syndrome differentiation classification of the TCM experts shall prevail. 5. The patient has good communication skills, can understand and provide relevant information required for the study, and is aware of the research purpose, content, possible risks and expected benefits can be fully provided with relevant information required for this research. Patients and their families voluntarily participated and agreed to sign the informed consent. Exclusion Criteria: 1. Those who have had acute coronary syndrome within the past month 2. Acute myocardial infarction, acute myocarditis, severe arrhythmia, aortic dissecction, pericarditis, heart failure (NYHA heart function class Ⅲ or IV, EF ≤ 30%), cardiogenic shock in past 3 months or patients with chest tightness and chest pain caused by other diseases such as severe valvular disease, etc. 3. Combined with acute pulmonary embolism, acute cerebral hemorrhage, polyarteritis, severe hematologic diseases, severe infectious diseases, severe immune dysfunction, malignant tumors, other organ failure or expected life expectancy less than 1 year 4. Severe primary disease or severe dysfunction of the liver or kidneys(ALT levels exceeding 3.0 times the upper limit of normal or eGFR ≤30 mL/min/1.73 m²) 5. Patients with severe mental disorder 6. Those who are allergic to the test drug 7. Patients who have participated in other clinical trials in the past month 8. Patients who have taken anticoagulants such as warfarin, new oral anticoagulants (NOAC) or traditional Chinese medicine preparations for promoting blood circulation and removing blood stasis in the past month 9. Refusal to sign informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fuwai hospital, CAMS&PUMC
RECRUITINGBeijing, Beijing Municipality, 100037, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can VR lessons help heart patients take their medicines?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Heart arteries without metal: CT scans track Drug-Coated balloon results
- Can a common gout pill shield hearts after stents?
- Can a simple blood test flag hidden heart risks after stenting?
- Community health workers take on heart disease prevention in cleveland